Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years - Concepedia

Concepedia

Publication | Open Access

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years

DOI Full Paper Access

214

Citations

21

References

2009

Year

Kevan C. Herold, Stephen E. Gitelman, Carla J. Greenbaum, Jennifer M. Puck, William Hagopian, Peter A. Gottlieb, Peter H. Sayre, Peter J. Bianchine, Emelita L. Wong, Vicki Seyfert‐Margolis,

Clinical Immunology

Type 1Translational MedicineInsulin ProductionDiabetes ManagementAutoimmune DiseaseInsulin ManagementDiabetesImmunologyAutoimmunityDiabetes MellitusInsulin DeliveryImmunotherapyMedicineAnti-cd3 Mab Teplizumab

References

	Year	Citations

Page 1

Page 1